Enspire DBS Therapy Announces $10.3 Million Series B1 Financing to Advance Pivotal Development of DBS-Enabled Stroke Rehabilitation

13 Jan 2026

View Full Article

Latest

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

11 December 2025

Antegrade Medical Announces the Closing of a $7.3M Seed Financing

28 October 2025

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

All Articles

January 13, 2026

Enspire DBS Therapy Announces $10.3 Million Series B1 Financing to Advance Pivotal Development of DBS-Enabled Stroke Rehabilitation

December 11, 2025

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

October 28, 2025

Antegrade Medical Announces the Closing of a $7.3M Seed Financing

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108